- Home
- OCFC vs AUPH Comparison
OCFC vs AUPH Comparison
Compare OCFC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- AUPH
- Stock Information
- Founded
- OCFC 1902
- AUPH 1993
- Country
- OCFC United States
- AUPH Canada
- Employees
- OCFC N/A
- AUPH N/A
- Industry
- OCFC Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- AUPH Health Care
- Exchange
- OCFC Nasdaq
- AUPH Nasdaq
- Market Cap
- OCFC 1.2B
- AUPH 1.3B
- IPO Year
- OCFC 1996
- AUPH 1999
- Fundamental
- Price
- OCFC $18.81
- AUPH $9.55
- Analyst Decision
- OCFC Hold
- AUPH Strong Buy
- Analyst Count
- OCFC 4
- AUPH 3
- Target Price
- OCFC $21.00
- AUPH $10.33
- AVG Volume (30 Days)
- OCFC 221.9K
- AUPH 1.5M
- Earning Date
- OCFC 01-16-2025
- AUPH 11-07-2024
- Dividend Yield
- OCFC 4.19%
- AUPH N/A
- EPS Growth
- OCFC N/A
- AUPH N/A
- EPS
- OCFC 1.74
- AUPH N/A
- Revenue
- OCFC $380,971,000.00
- AUPH $220,361,000.00
- Revenue This Year
- OCFC N/A
- AUPH $36.97
- Revenue Next Year
- OCFC $4.77
- AUPH $16.43
- P/E Ratio
- OCFC $11.22
- AUPH N/A
- Revenue Growth
- OCFC N/A
- AUPH 38.72
- 52 Week Low
- OCFC $14.03
- AUPH $4.71
- 52 Week High
- OCFC $21.87
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- OCFC 36.11
- AUPH 60.29
- Support Level
- OCFC $19.65
- AUPH $9.22
- Resistance Level
- OCFC $20.23
- AUPH $10.67
- Average True Range (ATR)
- OCFC 0.52
- AUPH 0.42
- MACD
- OCFC -0.23
- AUPH 0.01
- Stochastic Oscillator
- OCFC 2.89
- AUPH 43.15
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.